Dear , 

We are delighted to announce the launch of the Parkwalk UK Tech Fund VII, which will invest in 'hard science', knowledge intensive UK technology companies under the Enterprise Investment Scheme.

• Investing in companies predominantly spun-out from UK Universities based on significant Intellectual Property and/or commercial know-how
• The Fund will seek to make the majority of its investments in the 2016/17 tax year
• It will seek to have a maturity profile of investments which will include at least one early stage spin-out and at least one that is already in its commercialisation phase
• It is likely the fund will invest in some follow-on financing rounds in companies other Parkwalk funds have invested in and potentially alongside our Opportunities and/or the Parkwalk managed University of Oxford, Cambridge or Bristol Funds - this could allow a time-line of exits from around 4 to 8 years
• On each and any exit, cash will be returned to investors, less any fees due, rather than reinvested
• The fund will generally seek to invest alongside other financial institutions on similar terms (while complying with EIS regulations)

Please reply or email funds@parkwalkadvisors.com if you would like a copy of the prospectus.

Parkwalk's first investments were made in 2010 and so it is still relatively early days, but we believe Parkwalk is building an impressive track record:

• Both Parkwalk Funds I and II have each had two exits, and returned, in cash, more than the total amount that investors invested in each fund. Investors still have live investments in both funds
• Parkwalk's four exits since 2010 (two with gains, two with losses) have returned 2.25x cost (3.36x including tax reliefs) giving an IRR of 42% (or 54% including tax reliefs)
• As of January 2016, Fund I (invested between September 2010 & April 2011) has a NAV gain of 2.15x times (2.47x inc tax reliefs and fees) and Fund II (invested between May 2011 & April 2012) a gain of 2.36x times (2.92x inc tax reliefs and fees) 

Past performance is not necessarily a guide to future performance and may not necessarily be repeated

Parkwalk won the Investment Week ‘Best EIS Fund‘, Growth Investor ‘Best Exit 2015‘ award and the EIS Association ‘Best Exit of 2014‘, and has been named by Crunchbase as one of the UK’s top 10 most active technology investors in both 2014 and 2015.

Parkwalk seeks to align itself with the investor. We believe our track record highlights this. Both employees and managers of Parkwalk invest in our funds, in the same structure and shares as our investors.

Consistent with this philosophy, Parkwalk’s fees are predominantly performance driven. Parkwalk generally does not charge fees to investee companies.

As a result of these two policies, Parkwalk is incentivised to seek high cash returns in order to trigger performance fees.

INVESTING IN THIS SECTOR

2015 was an interesting year for UK University spin-outs as an asset class. Over $2bn was raised in the UK last year by four fund managers and institutions, taking their listed valuations to over $7bn. Highlights included IP Group raising $187m at 2.4 times NAV, the hugely succesful launch of Woodford's Patient Capital Trust and Oxford Sciences Innovation plc raising $450m.

These fund-raises were backed by the likes of Woodford, Invesco Perpetual, Landsdowne and Baillie Gifford.

Parkwalk has investments directly alongside such Funds as Woodford and Invesco (Xeros, Revolymer, First Light Fusion, Horizon Discovery, Sphere Medical) and indirectly with their investments in IP Group and Imperial Innovations.

Parkwalk EIS Funds invest in the same sector with our investors' effectively receiving a 30% discount to NAV once the tax reliefs of the EIS have been taken into account.

PARKWALK PROCESS & TIMING

Investors' subscriptions and shares are held at The Share Centre, the Funds' custodian and nominee.

in 2014/15, it took Parkwalk an average of approximately 9 months to fully deploy investors' subscriptions into underlying portfolio companies. 

In 2015, we made over 30 investments and in 2014/15 the average time it took to send EIS3s to individual investors was c.three months, with the shortest being one month and the longest five months (for an AIM-listed investment).

EIS TAX RELIEFS

The EIS offers UK taxpayers the following benefits:

• 30% Upfront Income Tax Relief
• Tax-Free Capital Gains
• Loss Relief of up to 61.5% for a 45% taxpayer
• CGT Deferral Relief
• IHT Exemption after 2 years

Please contact funds@parkwalkadvisors.com or call the funds team on 020 7759 2285 if you would like further details on the Parkwalk UK Tech Fund VII. 

Regards,

The Parkwalk Team  

This financial promotion is issued by Parkwalk Advisors Limited (Parkwalk), which is authorised and regulated by the Financial Conduct Authority. Investments referred to in this newsletter are not suitable for all investors.  Interested parties are strongly recommended to seek specialist financial and tax advice before investing in any product.  Capital is at risk and investors may not get back the full amount invested. Tax treatment depends on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results, and the value of investments may go down as well as up. Projections and forecasts are also not a reliable indicator of future performance. Investments in small and unquoted companies carry a higher risk than many other forms of investment. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Parkwalk is not able to provide advice as to the suitability of investing in any product.